Trial · NCT00658372
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
NCT00658372, Phase 3, Terminated, Pfizer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2). Trials, record NCT00658372. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00658372
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- NCT number
- NCT00658372
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 360 participants, actual
- Lead sponsor
- Pfizer
- Conditions
- Generalized Anxiety Disorder
- Interventions
- PD 0332334, PD 0332334, Paroxetine, Placebo
- First posted
- 2008-04-15
- Last updated
- 2012-11-16
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The efficacy of PD 0332334 in the treatment of GAD will be measured by the change in the Hamilton Anxiety Rating Scale (HAM-A) total scores from baseline observed following 8 weeks of double-blind treatment. | 8 weeks | |
| Primary | The safety and tolerability of PD 0332334 in subjects with GAD will be monitored in this study | 8 weeks | |
| Secondary | Average (across the week 1, 2, 4, 6 and 8 visits) HAM-A change from baseline score | 8 weeks | |
| Secondary | Change from baseline in the HAM-A total score at weeks 1, 2, 4, and 6 | 6 weeks | |
| Secondary | Change from Baseline to Week 8 on the Medical Outcomes Study Sleep Scale subscales | 8 weeks | |
| Secondary | Response rate on the patient-rated PGI-C at week 8 | 8 weeks | |
| Secondary | The "Week 1 Sustained Responder" rate based on the HAM A (where "Week 1 Sustained Responders" are defined as subjects with a 50% or greater improvement from baseline on the HAM A total score at Week 1 that is sustained until the Week 8 visit) | 1 week | |
| Secondary | Change from Baseline to Days 2- 8 and Weeks 2, 4, 6, 8 on the DAS A (total score) | 8 weeks | |
| Secondary | Change from Baseline to Week 8 on the Medical Outcomes Study Sleep Scale (MOS SS) Sleep Disturbance Score | 8 weeks | |
| Secondary | Response rate on the HAM-A at week 1 and week 8 | 8 weeks |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00658372
GET https://conductscience.org/api/trials/v1/NCT00658372/registered?page=2